209 related articles for article (PubMed ID: 33305893)
1. Anti-tumour effects of a dual cancer-specific oncolytic adenovirus on Breast Cancer Stem cells.
Li W; Li Y; Cui Y; Li S; Zhu Y; Shang C; Song G; Liu Z; Xiu Z; Cong J; Li T; Li X; Sun L; Jin N
J Cell Mol Med; 2021 Jan; 25(2):666-676. PubMed ID: 33305893
[TBL] [Abstract][Full Text] [Related]
2. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor effect of a dual cancer-specific recombinant adenovirus on ovarian cancer cells.
Cui Y; Li Y; Li S; Li W; Zhu Y; Wang J; Liu X; Yue Y; Jin N; Li X
Exp Cell Res; 2020 Nov; 396(1):112185. PubMed ID: 32828827
[TBL] [Abstract][Full Text] [Related]
4. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
5. A dual cancer-specific recombinant adenovirus suppresses the growth of liver cancer cells in vivo and in vitro.
Tian Y; Yao W; He D; Xu Y; Li Y; Zhu Y; Fang J; Bai B; Li X; Sun L; Jin N
Anticancer Drugs; 2020 Feb; 31(2):110-122. PubMed ID: 31658131
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Oncolytic Adenovirus Combined with Cyclophosphamide Induces Synergy in the Treatment of Breast Cancer in vitro and in vivo.
Wang J; Zuo S; Zhang Y; Li S; Shi Y; Du T; Han J; Jin N; Li Y; Li X
Cancer Manag Res; 2022; 14():2749-2761. PubMed ID: 36133740
[TBL] [Abstract][Full Text] [Related]
7. Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
Calaf GM; Ponce-Cusi R; Abarca-Quinones J
Oncol Rep; 2018 Jun; 39(6):2741-2748. PubMed ID: 29693159
[TBL] [Abstract][Full Text] [Related]
8. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of a dual cancer-specific oncolytic adenovirus on prostate cancer PC-3 cells.
Cui CX; Li YQ; Sun YJ; Zhu YL; Fang JB; Bai B; Li WJ; Li SZ; Ma YZ; Li X; Wang WH; Jin NY
Urol Oncol; 2019 Jun; 37(6):352.e1-352.e18. PubMed ID: 30665692
[TBL] [Abstract][Full Text] [Related]
10. Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus.
Ahtiainen L; Mirantes C; Jahkola T; Escutenaire S; Diaconu I; Osterlund P; Kanerva A; Cerullo V; Hemminki A
PLoS One; 2010 Nov; 5(11):e13859. PubMed ID: 21079774
[TBL] [Abstract][Full Text] [Related]
11. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
13. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
14. Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line.
Tan Z; Nie S; McDermott SP; Wicha MS; Lubman DM
J Proteome Res; 2017 Feb; 16(2):842-851. PubMed ID: 28076950
[TBL] [Abstract][Full Text] [Related]
15. Senescence evasion by MCF-7 human breast tumor-initiating cells.
Karimi-Busheri F; Rasouli-Nia A; Mackey JR; Weinfeld M
Breast Cancer Res; 2010; 12(3):R31. PubMed ID: 20525204
[TBL] [Abstract][Full Text] [Related]
16. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
[TBL] [Abstract][Full Text] [Related]
17. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
18. Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression.
Vesuna F; Lisok A; Kimble B; Raman V
Neoplasia; 2009 Dec; 11(12):1318-28. PubMed ID: 20019840
[TBL] [Abstract][Full Text] [Related]
19. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
[TBL] [Abstract][Full Text] [Related]
20. Association of CD44
Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
